Cardiovascular mortality ‐ not measured · people with implantable ventricular assist devices
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Rehospitalisation due to cardiovascular event ‐ not reported · people with implantable ventricular assist devices
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events: infection · people with implantable ventricular assist devices
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Health‐related quality of life · people with implantable ventricular assist devices
1 finding from 1 review
Heart transplantation ‐ not reported · people with implantable ventricular assist devices
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Costs ‐ not reported · people with implantable ventricular assist devices
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Physical fitness · People with cancer undergoing multimodal treatment including surgery
1 finding from 1 review
Safety · People with cancer undergoing multimodal treatment including surgery
1 finding from 1 review
Health‐related quality of life · People with cancer undergoing multimodal treatment including surgery
1 finding from 1 review
Fatigue · People with cancer undergoing multimodal treatment including surgery
1 finding from 1 review
Postoperative outcome · People with cancer undergoing multimodal treatment including surgery
1 finding from 1 review
Mortality at time point closest to 90 days · participants with internal medicine diseases and conditions
It is very uncertain whether short‐stay unit hospitalisation changes mortality at time point closest to 90 days compared with usual care (very low certainty).
1 finding from 1 review
RR 0.73 [0.47, 1.15]
1294 participants
Very low
Serious adverse events at time point closest to 90 days · participants with internal medicine diseases and conditions
It is very uncertain whether short‐stay unit hospitalisation changes serious adverse events at time point closest to 90 days compared with usual care (very low certainty).
1 finding from 1 review
RR 0.95 [0.59, 1.54]
1907 participants
Very low
Quality of life at time point closest to 90 days · participants with internal medicine diseases and conditions
1 finding from 1 review
no estimate extracted
1029 participants
Very low
Activities of daily living · participants with internal medicine diseases and conditions
1 finding from 1 review
no estimate extracted
569 participants
Very low
Patient readmissions · participants with internal medicine diseases and conditions
It is very uncertain whether short‐stay unit hospitalisation changes hospital readmission at time point closest to 90 days compared with usual care (very low certainty).
1 finding from 1 review
RR 0.8 [0.54, 1.19]
1753 participants
Very low
Non‐serious adverse events at time point closest to 90 days · participants with internal medicine diseases and conditions
1 finding from 1 review
no estimate extracted
533 participants
Very low
Costs · participants with internal medicine diseases and conditions
1 finding from 1 review
no estimate extracted
1433 participants
Very low
Exacerbations · autumn asthma exacerbations in children
Omalizumab probably leads to lower exacerbations compared with usual care (moderate certainty).
3 findings from 1 review
OR 0.48 [0.25, 0.92]
1 study · 348 participants
Moderate
OR 0.37 [0.17, 0.81]
1 study · 184 participants
Moderate
OR 0.63 [0.22, 1.79]
1 study · 164 participants
Moderate
Exacerbations · autumn asthma exacerbations in children
The review found no eligible studies for this question.
2 findings from 1 review